These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 22348983

  • 21. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
    Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R, HORIZON-PFT Research Group.
    J Bone Miner Res; 2009 Sep; 24(9):1544-51. PubMed ID: 19338427
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, Radovits B, Veale DJ, Fitzgerald O.
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Determinants of bone turnover markers in healthy premenopausal women.
    Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, DiMunno O, Frediani B, Rossini M, BONTURNO study group.
    Calcif Tissue Int; 2008 May; 82(5):341-7. PubMed ID: 18470550
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis].
    Bahlous A, Kalai E, Hadj Salah M, Bouzid K, Zerelli L.
    Tunis Med; 2006 Nov; 84(11):751-7. PubMed ID: 17294906
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women.
    Wu N, Wang QP, Li H, Wu XP, Sun ZQ, Luo XH.
    Clin Chim Acta; 2010 May 02; 411(9-10):771-5. PubMed ID: 20184866
    [Abstract] [Full Text] [Related]

  • 32. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM.
    Osteoporos Int; 2019 Mar 02; 30(3):667-673. PubMed ID: 30635696
    [Abstract] [Full Text] [Related]

  • 33. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 34. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T, Ke HZ, Simmons H, Thompson D.
    Clin Calcium; 2004 Oct 01; 14(10):85-93. PubMed ID: 15577137
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease.
    Furman K, Gut P, Sowińska A, Ruchała M, Fichna M.
    Endocrine; 2024 May 01; 84(2):711-719. PubMed ID: 38334892
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes.
    Goldstein SR, Neven P, Cummings S, Colgan T, Runowicz CD, Krpan D, Proulx J, Johnson M, Thompson D, Thompson J, Sriram U.
    Menopause; 2011 Jan 01; 18(1):17-22. PubMed ID: 20689465
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.